医疗与消费周报：创新药械多元支付：多元体系建立势在必行-20250430

Group 1 - The report emphasizes the necessity of establishing a diversified payment system for innovative drugs and medical devices in China, as the current single medical insurance payment model cannot meet the demand for high-priced innovative therapies [3][8][9] - According to the report, the market size for innovative drugs and medical devices in China is expected to reach 1.62 trillion yuan in 2024, representing a 16% year-on-year growth, with personal cash expenditure accounting for 49% and medical insurance fund expenditure approximately 44% [3][8] - The report highlights that the commercial health insurance sector in China is projected to reach a premium scale of 977.3 billion yuan in 2024, but it still faces challenges in terms of operational mechanisms and payment convenience [3][8][9] Group 2 - The report reviews the performance of the pharmaceutical sector from April 21 to April 25, noting that only three out of six sub-industries recorded positive returns, with the medical services and chemical pharmaceuticals leading the gains at +3.38% and +2.71% respectively [10] - The report indicates that the valuation levels for the chemical pharmaceuticals and biological products sectors are the highest at 70.86 times and 60.16 times respectively, while the lowest are for traditional Chinese medicine and pharmaceutical commerce at 29.79 times and 20.75 times [10][15] - The report tracks several industry hotspots, including the establishment of a biological sample library in Hangzhou, the pilot program for pre-hospitalization medical insurance payments in Beijing, and the recent policy allowing the import of cow bile for traditional Chinese medicine production [18][21][22]